Synthetic dipeptide derived from thymopoietin studied as an immunomodulator; approved in Russia.
Dipeptide (L-glutamyl-L-tryptophan). Proposed immunomodulatory effects on T-cell populations and cytokine profile.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Approved in Russia. Research peptide in US.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for Thymogen. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.
Showing 20 of 30 papers. View all on PubMed →